Our current results indicate that SLC2A1-AS1 may play an essential role in driving tumorigenesis, progression and glycolysis, and SLC2A1-AS1/miR-378a-3p/Glut1 signal axis may be a novel therapeutic target for ESCC patients. Here, SLC2A1 is linked to esophageal squamous cell carcinoma.